Imre Kovesdi

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2548880/imre-kovesdi-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

5,381
papers

5,381
citations

73
g-index

74
ext. papers

8.6
avg, IF

L-index

#	Paper	IF	Citations
68	Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality <i>Cureus</i> , 2022 , 14, e22750	1.2	0
67	Therapeutic Exploitation of Viral Interference. Infectious Disorders - Drug Targets, 2020, 20, 423-432	1.1	6
66	Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs. <i>Hepatology, Medicine and Policy,</i> 2018 , 3, 2		3
65	Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies. <i>Journal of Gene Medicine</i> , 2015 , 17, 116-31	3.5	7
64	Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. <i>PLoS ONE</i> , 2012 , 7, e46981	3.7	26
63	Recombinant infectious bursal disease virus carrying hepatitis C virus epitopes. <i>Journal of Virology</i> , 2011 , 85, 1408-14	6.6	12
62	Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging. <i>PLoS ONE</i> , 2011 , 6, e16792	3.7	10
61	Adenoviral producer cells. <i>Viruses</i> , 2010 , 2, 1681-703	6.2	52
60	Promoters influence the kinetics of transgene expression following adenovector gene delivery. Journal of Gene Medicine, 2008, 10, 123-31	3.5	21
59	Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes. <i>Molecular Biotechnology</i> , 2007 , 35, 263-73	3	17
58	Targeted and shielded adenovectors for cancer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 1412-9	7.4	39
57	Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. <i>Journal of Virology</i> , 2006 , 80, 5523-30	6.6	61
56	Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. <i>Journal of Clinical Investigation</i> , 2005 , 115, 1281-9	15.9	74
55	In vivo expression and function of recombinant GTPCH I in the rabbit carotid artery. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004 , 286, H570-4	5.2	6
54	Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. <i>Cancer Research</i> , 2004 , 64, 1386-95	10.1	64
53	Delayed angiogenesis in aging rats and therapeutic effect of adenoviral gene transfer of VEGF. <i>International Journal of Molecular Medicine</i> , 2004 , 13, 581	4.4	0
52	Adenovirus vectors targeting alphaV integrin or heparan sulfate receptors display different distribution of transgene activity after intramuscular injection. <i>Journal of Gene Medicine</i> , 2004 , 6, 309-100 distribution of transgene activity after intramuscular injection.	6 ^{3.5}	3

(1999-2003)

51	Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. <i>Molecular Therapy</i> , 2003 , 7, 597-603	11.7	39
50	In vivo gene transfer of inducible nitric oxide synthase to carotid arteries from hypercholesterolemic rabbits. <i>Stroke</i> , 2003 , 34, 1293-8	6.7	17
49	Regulation of tissue factor expression in smooth muscle cells with nitric oxide. <i>Journal of Vascular Surgery</i> , 2003 , 37, 650-9	3.5	4
48	Adenovirus vector library: an approach to the discovery of gene and protein function. <i>Journal of General Virology</i> , 2003 , 84, 3417-3422	4.9	7
47	Inhibitory effect of recombinant iNOS gene expression on vasomotor function of canine basilar artery. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 283, H2560-6	5.2	19
46	Rapid construction of adenoviral vectors by lambda phage genetics. <i>Journal of Virology</i> , 2002 , 76, 3670	- 7 6.6	18
45	Potentiation of nitric oxide-induced apoptosis in p53-/- vascular smooth muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , 2002 , 282, C625-34	5.4	21
44	Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. <i>Journal of Vascular Surgery</i> , 2001 , 34, 156-65	3.5	77
43	Adenoviral mediated delivery of FAS ligand to arthritic joints causes extensive apoptosis in the synovial lining. <i>Journal of Gene Medicine</i> , 2000 , 2, 210-9	3.5	54
42	Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. <i>Journal of Vascular Surgery</i> , 2000 , 31, 1214-2	3.5 28	103
41	Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. <i>Circulation</i> , 2000 , 102, 565-71	16.7	115
40	Nitric oxide prevents p21 degradation with the ubiquitin-proteasome pathway in vascular smooth muscle cells. <i>Journal of Vascular Surgery</i> , 2000 , 31, 364-74	3.5	28
39	Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 1031-9	15.1	116
38	Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. <i>Journal of Clinical Investigation</i> , 2000 , 106, 763-71	15.9	182
37	Endothelial nitric oxide synthase protects aortic allografts from the development of transplant arteriosclerosis. <i>Transplantation</i> , 2000 , 69, 1186-92	1.8	42
36	Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. <i>Human Gene Therapy</i> , 1999 , 10, 1633-40	4.8	74
35	Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1999 , 118, 339-47	1.5	26
34	Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector. Journal of Gene Medicine, 1999 , 1, 103-10	3.5	37

33	Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle. <i>Journal of Gene Medicine</i> , 1999 , 1, 393-9	3.5	26
32	Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. <i>Science</i> , 1999 , 286, 1568-71	33.3	363
31	Optimization of ex vivo inducible nitric oxide synthase gene transfer to vein grafts. <i>Surgery</i> , 1999 , 126, 323-329	3.6	28
30	Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. <i>Journal of Virology</i> , 1999 , 73, 9130-6	6.6	73
29	CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. <i>Journal of Clinical Investigation</i> , 1999 , 103, 579-87	15.9	176
28	Augmentation of pulmonary host defense against Pseudomonas by FcgammaRIIA cDNA transfer to the respiratory epithelium. <i>Journal of Clinical Investigation</i> , 1999 , 104, 409-18	15.9	3
27	Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. <i>Journal of Clinical Investigation</i> , 1999 , 104, 1245-55	15.9	177
26	Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998 ,	1.5	264
25	Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. <i>Journal of the American College of Surgeons</i> , 1998 , 187, 295-306	4.4	198
24	Adenovirus-mediated inducible nitric oxide synthase gene transfer inhibits hepatocyte apoptosis. <i>Surgery</i> , 1998 , 124, 278-283	3.6	72
23	Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. <i>Journal of Biological Chemistry</i> , 1998 , 273, 5815-20	5.4	83
22	The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. <i>Journal of Virology</i> , 1998 , 72, 7909-15	6.6	515
21	Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. <i>Human Gene Therapy</i> , 1997 , 8, 99-109	4.8	177
20	Myoblast-MediatedEx VivoGene Transfer to Mature Muscle. <i>Tissue Engineering</i> , 1997 , 3, 125-133		20
19	Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. <i>Surgery</i> , 1997 , 122, 255-63	3.6	141
18	Adenoviral vectors for gene transfer. <i>Current Opinion in Biotechnology</i> , 1997 , 8, 583-9	11.4	178
17	Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. <i>Nature Biotechnology</i> , 1996 , 14, 1570-3	44.5	293
16	"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. <i>Human Gene Therapy</i> , 1996 , 7, 79-87	4.8	182

LIST OF PUBLICATIONS

15	Structure of the gene coding for the human retinoic acid-inducible factor, MK. <i>DNA and Cell Biology</i> , 1993 , 12, 139-47	3.6	8
14	Expression of the HBNF (heparin-binding neurite-promoting factor) gene in the brain of fetal, neonatal and adult rat: an in situ hybridization study. <i>Developmental Brain Research</i> , 1992 , 70, 267-78		47
13	HBNF and MK, members of a novel gene family of heparin-binding proteins with potential roles in embryogenesis and brain function. <i>Progress in Growth Factor Research</i> , 1991 , 3, 143-57		55
12	Isolation from bovine brain and structural characterization of HBNF, a heparin-binding neurotrophic factor. <i>Growth Factors</i> , 1991 , 4, 97-107	1.6	31
11	Cloning, characterization and developmental regulation of two members of a novel human gene family of neurite outgrowth-promoting proteins. <i>Growth Factors</i> , 1991 , 5, 99-114	1.6	67
10	Structure/activity relationships in basic FGF. Annals of the New York Academy of Sciences, 1991, 638, 98-	16.8	19
9	Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins. <i>Biochemical and Biophysical Research Communications</i> , 1990 , 172, 850-4	3.4	56
8	Transactivation by the adenovirus E1A gene. <i>Biochemistry and Cell Biology</i> , 1988 , 66, 578-83	3.6	18
7	Developmental control of a promoter-specific factor that is also regulated by the E1A gene product. <i>Cell</i> , 1987 , 48, 501-6	56.2	118
6	A factor discriminating between the wild-type and a mutant polyomavirus enhancer. <i>Nature</i> , 1987 , 328, 87-9	50.4	48
5	Identification of a cellular transcription factor involved in E1A trans-activation. <i>Cell</i> , 1986 , 45, 219-28	56.2	538
4	Actin gene number in the sea star Pisaster ochraceus. <i>Canadian Journal of Biochemistry and Cell Biology</i> , 1985 , 63, 1145-1151		6
3	Actin genes from the sea star Pisaster ochraceus. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1984 , 782, 76-86		10
2	Sequence complexity in the maternal RNA of the starfish Pisaster ochraceus (Brandt). <i>Developmental Biology</i> , 1982 , 89, 56-63	3.1	7
1	The clinically validated viral superinfection therapy (SIT) platform technology could cure early cases of COVID-19 disease		2